YB-101 (GS-098)

About Yarrow Bioscience

Yarrow Bioscience's mission is to develop breakthrough antibody therapeutics for thyroid autoimmune diseases, starting with its lead candidate YB-101 targeting the thyroid-stimulating hormone receptor (TSHR). Its key achievement is securing a Nasdaq listing and approximately $200 million in financing through a strategic merger with VYNE Therapeutics, positioning it to fund operations into 2028. The company's strategy is highly focused, centering on the global ex-China development of YB-101, with planned Phase 1b/2b trials in Graves' disease and a parallel Phase 1 trial in thyroid eye disease conducted by its partner in China.

About Yarrow Bioscience

Yarrow Bioscience's mission is to develop breakthrough antibody therapeutics for thyroid autoimmune diseases, starting with its lead candidate YB-101 targeting the thyroid-stimulating hormone receptor (TSHR). Its key achievement is securing a Nasdaq listing and approximately $200 million in financing through a strategic merger with VYNE Therapeutics, positioning it to fund operations into 2028. The company's strategy is highly focused, centering on the global ex-China development of YB-101, with planned Phase 1b/2b trials in Graves' disease and a parallel Phase 1 trial in thyroid eye disease conducted by its partner in China.

About Vyne Therapeutics

VYNE Therapeutics is a clinical-stage biopharma company with a mission to solve difficult therapeutic challenges by questioning traditional assumptions. Its core asset is the InhiBET™ platform for developing topical and oral BET inhibitors, with lead candidate VYN201 in Phase 1b for vitiligo. The company's near-term future is defined by a pending all-stock merger with Yarrow Bioscience, announced in December 2025, which will bring a new lead program (YB-101 for Graves' disease) and approximately $200 million in capital, aiming to create a new entity focused on autoimmune endocrinology.

Therapeutic Areas